Michael D. Shafer, Executive Vice President at Thermo Fisher Scientific Inc., filed a Form 4 with the SEC on August 13, 2026, disclosing stock option exercises and sales of common stock that took place on August 11, 2026.

Key Highlights

  • Reporting person: Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific Inc. (NYSE:TMO)
  • Option exercise 1: 11,200 shares acquired via stock option exercise at an exercise price of $309.63 per share on August 11, 2026
  • Option exercise 2: 14,300 shares acquired via stock option exercise at an exercise price of $418.32 per share on August 11, 2026
  • Shares sold: Both the 11,200 and 14,300 share lots were disposed of at $600 per share on August 11, 2026, each coded as "S" transactions
  • Beneficial ownership after transactions: 20,994.0336 shares of common stock held directly following all reported transactions
  • Rule 10b5-1 plan: Sales were effected pursuant to a trading plan adopted by Shafer on December 11, 2025, according to the filing

Option Exercises and Share Sales by Thermo Fisher Scientific Executive Vice President

According to the filing, Shafer exercised two tranches of stock options on August 11, 2026. The first tranche involved 11,200 shares acquired at an exercise price of $309.63, corresponding to options that vested in four equal installments on February 25 of 2021, 2022, 2023, and 2024, with an expiration date of February 25, 2027. The second tranche covered 14,300 shares at an exercise price of $418.32, with an expiration date of September 9, 2027. Both option positions were reduced to zero following the exercises, as disclosed in Table II of the filing.

Following each option exercise, the filing reports that the acquired shares were sold. Both the 11,200-share and 14,300-share lots were disposed of at a price of $600 per share, each recorded with transaction code "S" in Table I. The filing notes that these sales were made under a Rule 10b5-1 trading plan that Shafer adopted on December 11, 2025. After all four transactions were completed, Shafer's direct beneficial ownership stood at 20,994.0336 shares of Thermo Fisher Scientific common stock.

The filing also notes that the post-transaction share count includes 44.079 shares acquired under the issuer's employee stock purchase plan on May 15, 2026. The Form 4 was signed by Melodie T. Morin as Attorney-in-Fact for Michael D. Shafer and dated August 13, 2026. Thermo Fisher Scientific is a life sciences company listed on the New York Stock Exchange.

What Was Disclosed

The filing disclosed stock option exercises totaling 25,500 shares and corresponding open-market sales by Thermo Fisher Scientific's Executive Vice President on August 11, 2026, with all transactions conducted under a pre-established Rule 10b5-1 trading plan adopted in December 2025.